<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00516607</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-26054</org_study_id>
    <secondary_id>EORTC-26054</secondary_id>
    <nct_id>NCT00516607</nct_id>
  </id_info>
  <brief_title>Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas</brief_title>
  <official_title>Phase I Study of Enzastaurin and Temozolomide in Patients With Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,&#xD;
      such as temozolomide, work in different ways to stop the growth of tumor cells, either by&#xD;
      killing the cells or by stopping them from dividing. Giving enzastaurin together with&#xD;
      temozolomide may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of enzastaurin when&#xD;
      given together with temozolomide in treating patients with primary gliomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To assess if full doses of enzastaurin hydrochloride and temozolomide can be used in&#xD;
           combination for the treatment of patients with primary gliomas.&#xD;
&#xD;
        -  To determine the recommended phase II dose.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral enzastaurin hydrochloride once or twice daily on days 1-28* and oral&#xD;
      temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      NOTE: *During the first course only, patients also receive enzastaurin hydrochloride on day&#xD;
      -1.&#xD;
&#xD;
      Patients undergo blood sample collection on day 22 of course 1 and on day 5 of course 2 for&#xD;
      pharmacokinetic studies of enzastaurin hydrochloride.&#xD;
&#xD;
      After completion of study treatment, patients are followed within 30 days and then every 3&#xD;
      months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended phase II dose</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of enzastaurin hydrochloride alone and in combination with temozolomide</measure>
  </secondary_outcome>
  <enrollment type="Actual">28</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enzastaurin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary supratentorial glioma&#xD;
&#xD;
               -  WHO histologic grade 3 or 4&#xD;
&#xD;
                    -  Patients who have undergone prior treatment for low-grade glioma that has&#xD;
                       transformed to glioblastoma (biopsy proven) allowed&#xD;
&#xD;
          -  Amenable to standard temozolomide treatment&#xD;
&#xD;
          -  First or second recurrent disease after prior surgery and/or radiotherapy OR newly&#xD;
             diagnosed disease that is not amenable to radiotherapy (e.g., multifocal disease)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG or WHO performance status 0-2&#xD;
&#xD;
          -  Hemoglobin ≥ 10.0 g/dL&#xD;
&#xD;
          -  Neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase and transaminases ≤ 2.5 x ULN&#xD;
&#xD;
          -  Serum creatinine &lt; 1.7 mg/dL&#xD;
&#xD;
          -  Not pregnant or lactating&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Clinically normal cardiac function&#xD;
&#xD;
          -  No ischemic heart disease within the past 6 months&#xD;
&#xD;
          -  No clinically significant abnormalities or uncontrolled cardiac arrhythmia by ECG&#xD;
&#xD;
          -  QTc interval ≤ 450 msec (males) or ≤ 470 msec (females) by baseline 12-lead ECG&#xD;
&#xD;
          -  No history of congenital long QTc syndrome&#xD;
&#xD;
          -  No history of stroke&#xD;
&#xD;
          -  No other prior or concurrent malignancy within the past 5 years except cone biopsied&#xD;
             carcinoma of the cervix or adequately treated basal or squamous cell skin carcinoma&#xD;
&#xD;
          -  No unstable systemic diseases&#xD;
&#xD;
          -  No active uncontrolled infections&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study participation&#xD;
&#xD;
          -  Must be able to swallow tablets&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen in the adjuvant setting or for first&#xD;
             recurrence&#xD;
&#xD;
          -  Prior temozolomide allowed provided there was no disease progression during&#xD;
             temozolomide treatment or within 6 weeks of completing temozolomide treatment&#xD;
&#xD;
          -  Prior surgery for primary brain tumor within the past 3 months allowed&#xD;
&#xD;
          -  Patients who are receiving corticosteroid treatment must be on a stable or decreasing&#xD;
             dose for at least 1 week before study entry&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  At least 14 days since prior and no concurrent enzyme-inducing antiepileptic drugs&#xD;
             including, but not limited to, any of the following:&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
          -  More than 30 days since prior and no other concurrent investigational treatments&#xD;
&#xD;
          -  No concurrent anticoagulant treatment (e.g., warfarin)&#xD;
&#xD;
               -  Low molecular weight heparin for patients who require anticoagulant therapy after&#xD;
                  starting study treatment may be allowed&#xD;
&#xD;
          -  No concurrent routine use of colony-stimulating factors&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy Rampling, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Rampling R, Sanson M, Gorlia T, Lacombe D, Lai C, Gharib M, Taal W, Stoffregen C, Decker R, van den Bent MJ. A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). Neuro Oncol. 2012 Mar;14(3):344-50. doi: 10.1093/neuonc/nor221. Epub 2012 Jan 29.</citation>
    <PMID>22291006</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>August 14, 2007</study_first_submitted>
  <study_first_submitted_qc>August 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2007</study_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult pineal gland astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

